🔎 Trials Near Me

Pradžia › Antsvoris › Nevada

Antsvoris klinikiniai tyrimai Nevada

24 tyrimai dėl Antsvoris ieško dalyvių vietose Nevada.

Miestai Nevada

Oficialus tyrimo tekstas (anglų kalba)

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

  • Vector Clinical Trials /ID# 282265, Las Vegas
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-10-02 · NCT07752979

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

  • Palm Research Center Inc., Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT07720271

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  • M3 Wake Research - Las Vegas Cimarron, Las Vegas
  • Renascor Clinical Research, Reno
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT07794579

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  • Palm Research Center Tenaya, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT07369011

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • Excel Clinical Research, Las Vegas
  • Vector Clinical Trials, Las Vegas
Renkami dalyviai3 fazė
Amžius nuo 45 iki 99 · Visoms lytims · Atnaujinta 2026-09-22 · NCT07037433

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  • AMR Clinical, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT07321886

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  • Las Vegas Medical Research, Las Vegas
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-22 · NCT07589608

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  • AURORA-1 Clinical Site, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-16 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-16 · NCT07743450

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

  • ACCOMPLISH-2 Research Site, Las Vegas
Renkami dalyviai3 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 79 · Visoms lytims · Atnaujinta 2026-09-11 · NCT07654374

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

  • Jubilee Clinical Research, Inc., Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-09 · NCT07770841

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  • Las Vegas Medical Research, Las Vegas
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-08 · NCT06143956

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

  • Vector Clinical Trials, Las Vegas
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-08 · NCT07215559

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • Kailera Clinical Site, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-03 · NCT07284901

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  • Palm Research Center Inc, Las Vegas
  • Vector Clinical Trials, Las Vegas
Renkami dalyviai3 fazė
Amžius nuo 18 iki 99 · Visoms lytims · Atnaujinta 2026-09-03 · NCT07684235

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  • Kailera Clinical Site, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-03 · NCT07284875

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

  • Palm Research Center Inc, Las Vegas
Renkami dalyviai3 fazė
Amžius nuo 18 iki 99 · Visoms lytims · Atnaujinta 2026-09-03 · NCT07684144

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  • Excel Clinical Research, Las Vegas
Renkami dalyviai3 fazė
Amžius nuo 18 iki 99 · Visoms lytims · Atnaujinta 2026-08-27 · NCT07575399

Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.

  • University of Nevada, Las Vegas, Las Vegas
Renkami dalyviaiLaukiami sveiki savanoriai
Amžius nuo 21 iki 74 · Visoms lytims · Atnaujinta 2026-08-27 · NCT07566325

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  • Research Site, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-25 · NCT07784725

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

  • ACCOMPLISH-1 Research Site, Las Vegas
Renkami dalyviai3 fazė
Amžius nuo 18 iki 79 · Visoms lytims · Atnaujinta 2026-08-10 · NCT07654361

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

  • Corxel Investigational site, Las Vegas
Renkami dalyviai1 fazė
Amžius nuo 18 iki 55 · Moterims · Atnaujinta 2026-06-17 · NCT07652047

Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.